This trial will compare the outcomes of two different strategies for managing concomitant CAD in patients undergoing TAVR: complete revascularization vs. medical therapy alone.
- Coronary Artery Disease
- Coronary Artery Stenosis
- Aortic Stenosis
1 Primary · 22 Secondary · Reporting Duration: Median follow-up of 3.5 years
Awards & Highlights
2 Treatment Groups
Medical Therapy Alone
1 of 2
1 of 2
4000 Total Participants · 2 Treatment Groups
Primary Treatment: Percutaneous Coronary Intervention (PCI) · No Placebo Group · N/A
Who is running the clinical trial?
Age Any Age · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there still opportunities for prospective participants to take part in this clinical investigation?
"Affirmative. According to the clinicaltrials.gov portal, this experiment is currently recruiting volunteers. It was first advertised on December 19th of 2020 and most recently updated on March 31st 2022 with a goal to secure 4000 participants from 26 separate locations." - Anonymous Online Contributor
To what extent is the recruitment process for this clinical trial progressing?
"Affirmative, according to clinicaltrials.gov's database this research is actively recruiting. This investigation was initially posted on December 19th 2020 and has been recently modified on March 31st 2022. 4000 patients are necessary for the trial at 26 centers across the country." - Anonymous Online Contributor
Where are the primary venues of this clinical experiment?
"This clinical trial has recruited participants from a total of 26 sites, such as St. Joseph Mercy Health System in Ypsilanti, University of Minnesota Medical Center in Minneapolis, and Parkview Research Center in Fort Wayne." - Anonymous Online Contributor